Ensysce Biosciences (ENSCW) Convertible Debt (2020 - 2021)
Ensysce Biosciences (ENSCW) reported Convertible Debt of $16.8 million for Q4 2021, up 2406.46% year-over-year from $670262.0 in Q4 2020, and up 296.85% quarter-over-quarter from $4.2 million in Q3 2021.
Ensysce Biosciences (ENSCW) Convertible Debt (2020 - 2021) Analysis & Trends
Ensysce Biosciences (ENSCW) has 2 years of Convertible Debt data on file, last reported at $16.8 million in Q4 2021.
- Convertible Debt for Q4 2021 came in at $16.8 million, up 2406.46% year-over-year; the trailing twelve-month figure through Dec 2021 was $16.8 million (up 2406.46% YoY), and the FY2021 annual result was $16.8 million, up 2406.46% from the prior year.
- Convertible Debt grew to $16.8 million in Q4 2021 per ENSCW's latest filing, from $4.2 million in the prior quarter.
- Over five years, Convertible Debt peaked at $16.8 million in Q4 2021 and troughed at $670262.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 16.80 Mn |
| Sep 30, 2021 | 4.23 Mn |
| Dec 31, 2020 | 670,262.00 |
| Mar 31, 2020 | 1.00 Mn |